Welcome to our dedicated page for MEDICAL CARE TECHS news (Ticker: MDCE), a resource for investors and traders seeking the latest updates and insights on MEDICAL CARE TECHS stock.
Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (MDCE) announced that subsidiaries Infinite Auctions and Real Game Used have executed a transactional agreement with Fanatics / Topps to supply and authenticate game-worn sports memorabilia for Topps trading card products.
Infinite Auctions will sell game-worn items to Topps, while Real Game Used will provide AI-enhanced photo-match authentication to support product integrity. Fanatics reported about $8.1 billion in 2024 revenue, with its Topps-powered collectibles division at about $1.6 billion and expected by the company to approach $3 billion in 2026. MDCE states the agreement does not guarantee specific revenue or volume and highlights ongoing development of its AI vision projects, including Melanoma Scan Beta, a wound care app, and StrainScan Pro.
Medical Care Technologies (MDCE) reported progress on its StrainScan Pro platform by moving its foodservice application into custom demonstrations for commercial kitchens and multi-unit operators.
The AI vision software, already positioned for both agriculture and foodservice, now follows its farm-side demo work with kitchen-focused sessions built around receiving checks, line-level visual review, and consistency monitoring across single or multiple sites. StrainScan Pro runs on portable iPad Air devices, aiming to bring visual quality analysis from packing environments into kitchens in the global restaurant and foodservice market, which is estimated near $4 trillion. The company emphasized that this update reflects platform advancement rather than any commercial contract award.
Medical Care Technologies (MDCE) is configuring its StrainScan Pro AI vision platform for high-value, highly perishable crops including leafy greens, berries, tomatoes and tree fruit. The software is designed for on-device analysis and portable deployment on iPad Air hardware, supporting inspection in fields, on packing lines and at post-harvest checkpoints.
The company is building crop-specific visual modules tuned to traits that affect grade, shelf life and rejection risk, such as surface defects, color inconsistency, bruising and wilting. Development priorities are based on feedback from early operator sessions and are focused on crops where visual defects and spoilage can rapidly destroy value. This update reflects ongoing configuration work and is not a commercial contract award.
Medical Care Technologies (MDCE) reports that initial StrainScan Pro demonstrations with agricultural operators are underway and generating feedback that is directly shaping the platform’s next development cycle.
The proprietary AI vision software is built for agricultural and foodservice use and is designed for portable deployment on iPad Air devices to support visual quality analysis in the field, at packing points, and other production decision points. Early demos have focused on produce inspection, visual grading, consistency checks, and early detection of quality issues. Operator input is being used to add workflow depth, speed on-device review, clarify comparison steps, and create additional quality-check paths. The company positions StrainScan Pro as a scalable visual quality platform for a global agricultural market often estimated at $4.8–$5 trillion in gross production value.
Medical Care Technologies (MDCE) on September 8, 2026 highlighted a multi-platform AI business spanning health, enterprise imaging, consumer apps, and revenue-generating subsidiaries.
The company is advancing Melanoma Scan Beta, an AI-assisted skin imaging and body-map monitoring app that remains in beta, lacks regulatory clearance, and is not intended for diagnosis or treatment. Work includes internal testing on public dermatology datasets and volunteer image intake. StrainScan Pro targets agriculture and foodservice quality uses, with custom demos for enterprise clients and planned portable deployment on iPad Air. Snapshot Recipes is a live consumer mobile app, while subsidiaries Infinite Auctions and Real Game Used operate in online auctions and memorabilia authentication.
Medical Care Technologies (MDCE) has opened volunteer intake for the first human-submitted image cohort supporting its MDCE Melanoma Scan Beta testing initiative, following an earlier August 31, 2026 announcement.
The project moves beyond public cancer imaging datasets such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts by adding real-world user images. Volunteer images are expected to be used only for internal model evaluation, workflow and intake testing, body-map organization review, and longitudinal comparison functions. The company emphasizes that this is a development and testing process, not a clinical diagnosis program, and the beta platform has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent disease.
Medical Care Technologies (MDCE) is preparing the first custom enterprise demonstrations of its StrainScan Pro AI vision platform for agricultural clients. The software targets visual inspection, quality grading, consistency checks, and early issue detection across farming and post-harvest operations, optimized for portable use on iPad Air devices. The tailored demos are built around real operating conditions, such as produce inspection and crop-stress anomaly detection, to show how workflows can be adapted. The company emphasizes that these demonstrations are part of its enterprise development process and do not represent commercial contracts, while it continues to generate revenue through operating subsidiaries.
Medical Care Technologies (MDCE) highlighted ongoing development of its MDCE Melanoma Scan Beta, an AI-assisted imaging and body-map monitoring application designed to help users organize and compare visible skin images over time to support early awareness of potential melanoma warning signs.
The company frames the effort against 2026 American Cancer Society estimates of about 112,000 new invasive melanoma cases and 8,510 deaths in the United States, noting the large survival gap between localized and distant-stage disease. The beta-stage platform offers an interactive body-map interface for cataloging images, tracking changes across sessions, and flagging visuals for professional review. It has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent disease. Medical Care Technologies continues internal testing and volunteer image evaluations as it refines AI-assisted visual review and comparison functions.
Medical Care Technologies (OTCID:MDCE) announced that its proprietary AI vision platform, StrainScan Pro, is being advanced specifically for the multi-trillion-dollar agriculture and foodservice markets. The software supports visual quality analysis, consistency checks, and early quality-issue identification across farming, post-harvest handling, commercial kitchens, and high-volume food environments.
According to Medical Care Technologies, StrainScan Pro is designed for portable use on iPad Air devices, enabling field, packing-point, and in-kitchen deployment without fixed industrial systems. The company notes that global agricultural and foodservice markets together represent trillions of dollars in annual economic activity. StrainScan Pro is positioned as an enterprise visual analysis platform and is not a medical diagnostic device. Medical Care Technologies states it is continuing to advance AI vision solutions across high-value verticals while generating revenue through its operating subsidiaries.
Medical Care Technologies (OTCID: MDCE) announced that its MDCE Melanoma Scan Beta platform is entering a new phase of testing by seeking its first volunteer cohorts to provide human-submitted skin images. This follows earlier development based on public dermatology datasets such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts.
According to the company, real-world user images are intended to introduce variability in lighting, devices, distance, skin tone, and image quality to better assess intake, workflow, body-map organization, and AI model performance. The beta-stage application is designed for image organization and longitudinal tracking, has no regulatory clearance, and is not intended for diagnosis or treatment.